Compare Palantir Technologies Inc (PLTR) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Twist Bioscience Corp — how do they compare? Palantir Technologies Inc trades at $200.02 (market cap $466.48B), while Twist Bioscience Corp trades at $157.83 (market cap $10.32B). The key difference: Palantir Technologies Inc is far larger — about 45.2× Twist Bioscience Corp's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 78 Days and Twist Bioscience Corp for 27 Days on average.
| PLTR | TWST | |
|---|---|---|
Market Cap | $466.48B | $10.32B |
Volume | 15,675,589 | 5,894,998 |
Sector | Technology | Health |
52-Week High | $207.18 | $205.00 |
52-Week Low | $107.27 | $25.45 |
Typical Hold Time | 78 Days | 27 Days |
Enterprise Value | $457.28B | $10.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $198.78, up 3.48% with strong bullish technical signals and consecutive earnings beats. The stock shows robust revenue growth from $1.9B in 2022 to $4.48B in 2025, with net income turning positive to $1.63B. Recent partnership with Armada for sovereign AI infrastructure and positive analyst coverage support momentum, though valuation ratios remain elevated.
Outlook remains positive with accelerating AI adoption and strong fundamentals, but high P/E of 165.91 and P/S of 81.08 present valuation risks. Analyst consensus price target of $185.58 suggests potential downside, while growth trajectory and institutional bullish sentiment offer upside potential amid competitive and execution risks.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
